Hereditary Angioedema Therapeutics Market To Reach $5.8 Billion By 2030

Hereditary Angioedema Therapeutics Market Growth & Trends

The global hereditary angioedema therapeutic market size is expected to reach USD 5.8 billion by 2030, according to a new report by Grand View Research, Inc., exhibiting a 7.4% CAGR from 2023 to 2030. Growing initiatives by international patient organizations to improve awareness about hereditary angioedema (HAE) among patients and healthcare providers is likely to be a high impact rendering driver for the market.

Patient advocacy organizations affiliated to HAE International (HAEi) are focusing on campaigns through both print and social media in order to raise awareness levels for hereditary angioedema. HAEi has also introduced family testing tools for improving patient awareness levels, which is likely to help in providing accurate diagnosis and optimal medical treatment. Pharmaceutical and biotechnology companies such as CSL Limited, Pharming Group N.V., and Shire Plc. engaged in development of therapies for HAE have also lent their support and collaborated with the hereditary angioedema community so as to create effective diagnosis process and treatment for the condition.

Universities in different countries across the globe are collaborating with each other in order to develop new therapies for the management of hereditary angioedema attacks. For instance, in 2018, 26 universities from Europe, Australia, and Canada collaborated on an international study to develop a novel oral therapy for prevention of the condition.

Measures undertaken by countries for improving patient access to new therapies, along with modification in regulatory guidelines for facilitating faster drug review and approval for HAE, are expected to contribute to market growth. For instance, in July 2018, China’s National Health Commission (NHC) and State Drug Administration (SDA) allowed pharmaceutical drug manufacturers to file for New Drug Application (NDA) for therapies for rare diseases whose treatment is currently not available in the country. The decision has allowed drug manufacturers to use clinical trial data from outside China while filing for NDA.

 Request a free sample copy or view report summary: Hereditary Angioedema Therapeutics Market Report

Hereditary Angioedema Therapeutics Market Report Highlights

• The C1-esterase inhibitor segment held the largest share in 2022 owing to high usage rates of the products in on-demand and prophylactic treatment of HAE

• On-demand treatment accounted for the dominant share in the market and is expected to witness lucrative growth over the forecast period. Expected launch of products in new geographies is likely to be a key growth driver for the segment

• North America dominated the overall hereditary angioedema therapeutics market in terms of revenue in 2022. Growing number of cases of the condition, favorable government programs, increasing awareness levels among patients, and presence of highly expert healthcare professionals are factors contributing to the major share of this regional market

• Asia Pacific is expected to register lucrative growth over the forecast period owing to improving healthcare infrastructure and high unmet medical needs. Moreover, launch of new therapies for the treatment of the condition is likely to facilitate market growth in the region

• Key players include Ionis Pharmaceuticals, Inc.; BioCryst Pharmaceuticals, Inc.; Pharming Group N.V.; CSL Limited; Shire plc; Adverum Biotechnologies, Inc.; Attune Pharmaceuticals, Inc.; and KalVista Pharmaceuticals, Inc.

Hereditary Angioedema Therapeutics Market Segmentation

Grand View Research has segmented the global hereditary angioedema therapeutics market report based on treatment, end-use, route of administration, and region

Hereditary Angioedema Therapeutics Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• C1-esterase inhibitor

• Bradykinin B2 receptor antagonist

• Kallikrein inhibitor

• Others

Hereditary Angioedema Therapeutics End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Prophylaxis

• On-demand

Hereditary Angioedema Therapeutics Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Intravenous

• Subcutaneous

• Oral

Hereditary Angioedema Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Hereditary Angioedema (HAE) Therapeutics Market

• BioCryst Pharmaceuticals, Inc.

• Ionis Pharmaceuticals

• CSL

• Attune Pharmaceuticals

• Adverum Biotechnologies, Inc.

• KalVista Pharmaceuticals, Inc.

• Takeda Pharmaceutical Company Limited

• Pharming